Annual Report Reveals 26% Profit Drop, North America Revenue Decline, and Key Regulatory Setbacks in China and US Biosimilars
Summary
Dr. Reddy's Laboratories reported a 26% profit decline and a 22% revenue drop in North America, alongside significant R&D impairments and regulatory challenges in China and the US biosimilar market.
Key Events
-
Significant Profit Decline
Net profit for the year ended March 31, 2026, decreased by 25.8% to Rs. 42,466 million (approximately $452 million) from Rs. 57,245 million in the prior year.
-
North America Revenue Drop
Revenues from North America (US and Canada) decreased by 22% to Rs. 113,737 million, primarily due to price erosion of existing products, including Lenalidomide.
-
Major R&D Impairments
The company recorded Rs. 3,519 million in non-current asset impairments, including Rs. 1,291 million from discontinuing CAR T therapy programs and Rs. 914 million from ending a Phase III study for Eftilagimod Alfa.
-
China Market Suspension
China's NMPA suspended the import, sale, and use of Atomoxetine Hydrochloride Capsules and barred the company from national centralized drug procurement until February 2026 due to GMP non-compliance.
Analysis
This annual report highlights a significant downturn in financial performance, with a 26% year-over-year drop in net profit and notable gross margin compression. A major concern is the 22% revenue decline in North America, primarily due to price erosion of key products like Lenalidomide. Operational challenges are evident with the discontinuation of two R&D programs leading to substantial impairment charges, and critical regulatory setbacks including a market suspension in China for Atomoxetine Hydrochloride Capsules due to GMP non-compliance and Complete Response Letters from the USFDA for two biosimilar applications (Rituximab and Denosumab). These issues collectively indicate significant headwinds and impact the company's near-term growth and profitability outlook.
At the time of this filing, RDY was trading at $13.63 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.5B. The 52-week trading range was $12.19 to $16.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.